Figure 5

TG2 expression predicts recurrence and metastasis in patients with breast cancer. TG2 expression was analyzed with immunohistochemistry in a tissue microarray of primary tumors from patients with advanced breast cancer. (a) Immunohistochemical staining for TG2 in the primary tumors of patients with breast cancer showing negative (upper) and strong expression (lower) (×200). (b) Recurrence-free survival and (c) distant metastasis-free survival according to TG2 expression adjusted for tumor size (≤2 cm versus > 2 cm), histologic grade (1, 2 versus 3), lymph node status (positive versus negative), and hormone-receptor status (positive versus negative). The mean follow-up duration for patients after surgery was 83.6 ± 29.8 months. (d)/////Table 1. Cox's proportional hazards regression models for recurrence-free and distant metastasis-free survival. TG2, transglutaminase 2.